Tag: RPE65-mediated inherited retinal disease

Spark Therapeutics bags Luxturna EU approval for inherited retinal disease

pharmanewsdaily- November 24, 2018

Luxturna EU approval for inherited retinal disease : Pennsylvania-based Spark Therapeutics has bagged the European Commission’s (EC) approval for its gene therapy Luxturna (voretigene neparvovec) ... Read More

US FDA approves Spark’s gene therapy Luxturna for rare form of vision loss

pharmanewsdaily- December 30, 2017

Luxturna FDA approval : Luxturna (voretigene neparvovec), a gene therapy from Spark Therapeutics has secured the approval from the US Food and Drug Administration (FDA) ... Read More

Panel recommends Luxturna FDA approval for rare form of blindness

pharmanewsdaily- October 15, 2017

Luxturna FDA approval news : Luxturna (voretigene neparvovec), a gene therapy from Spark Therapeutics is closing in towards an FDA approval for treating blindness due ... Read More